The V3 loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity

Journal of Virology

Volumn 91, Issue 7, 2017, Pages

  Wang, Yimeng ^a,b   Pan, Qinghua ^a   Ding, Shilei ^c   Wang, Zhen ^a,b   Yu, Jingyou ^d   Finzi, Andrés ^b,c   Liu, Shan Lu ^d   Liang, Chen ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Envelope protein; Human immunodeficiency virus; IFITM

Indexed keywords

CD4 ANTIGEN; INTERFERON INDUCIBLE TRANSMEMBRANE PROTEIN 3; MARAVIROC; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17B; PLERIXAFOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; IFITM3 PROTEIN, HUMAN; RNA BINDING PROTEIN;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; FOUNDER EFFECT; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN STRUCTURE; V3 LOOP; VIRUS ENTRY; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; IMMUNOLOGY; PHYSIOLOGY; PROTEIN MOTIF; VIRION; VIROLOGY;

AMINO ACID MOTIFS; HEK293 CELLS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; MEMBRANE PROTEINS; RNA-BINDING PROTEINS; VIRION;

EID: 85014502736     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02441-16     Document Type: Article

References (69)

1. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243-1254. https://doi.org/10.1016/j.cell.2009.12.017.
2. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7:e1001258. https://doi.org/10.1371/journal.ppat.1001258.
3. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. 2011. The IFITM proteins inhibit HIV-1 infection. J Virol 85:2126-2137. https://doi.org/10.1128/JVI.01531-10.
4. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84: 12646-12657. https://doi.org/10.1128/JVI.01328-10.
5. Bailey CC, Zhong G, Huang IC, Farzan M. 2014. IFITM-family proteins: the cell's first line of antiviral defense. Annu Rev Virol 1:261-283. https://doi.org/10.1146/annurev-virology-031413-085537.
6. Bailey CC, Huang IC, Kam C, Farzan M. 2012. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 8:e1002909. https://doi.org/10.1371/journal.ppat.1002909.
7. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, GenISIS Investigators, MOSAIC Investigators, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519-523. https://doi.org/10.1038/nature10921.
8. Zhang Y, Makvandi-Nejad S, Qin L, Zhao Y, Zhang T, Wang L, Repapi E, Taylor S, McMichael A, Li N. 2015. Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. AIDS 29:889-894. https://doi.org/10.1097/QAD.0000000000000632.
9. Zhang Y-H, Zhao Y, Li N, Peng Y-C, Giannoulatou E, Jin R-H, Yan H-P, Wu H, Liu J-H, Liu N. 2013. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun 4:1418. https://doi.org/10.1038/ncomms2433.
10. Diamond MS, Farzan M. 2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 13:46-57. https://doi.org/10.1038/nri3344.
11. Perreira JM, Chin CR, Feeley EM, Brass AL. 2013. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 425:4937-4955. https://doi.org/10.1016/j.jmb.2013.09.024.
12. Smith S, Weston S, Kellam P, Marsh M. 2014. IFITM proteins-cellular inhibitors of viral entry. Curr Opin Virol 4:71-77. https://doi.org/10.1016/j.coviro.2013.11.004.
13. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen L-M, Gaiha GD, Ryan BJ, Donis RO, Elledge SJ. 2011. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 7:e1002337. https://doi.org/10.1371/journal.ppat.1002337.
14. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. 2014. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog 10: e1004048. https://doi.org/10.1371/journal.ppat.1004048.
15. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, Gratton E, Cohen FS, Liu SL. 2013. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog 9:e1003124. https://doi.org/10.1371/journal.ppat.1003124.
16. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, Jung JU. 2013. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13:452-464. https://doi.org/10.1016/j.chom.2013.03.006.
17. Bailey CC, Kondur HR, Huang I-C, Farzan M. 2013. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem 288:32184-32193. https://doi.org/10.1074/jbc.M113.514356.
18. Jia R, Pan Q, Ding S, Rong L, Liu S-L, Geng Y, Qiao W, Liang C. 2012. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol 86:13697-13707. https://doi.org/10.1128/JVI.01828-12.
19. Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, Liu SL, Guo F, Geng Y, Qiao W. 2014. Identification of an endocytic signal essential for the antiviral action of IFITM3. Cell Microbiol 16:1080-1093. https://doi.org/10.1111/cmi.12262.
20. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, Smith SE, Elia AE, Everitt AR, Vora M. 2013. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. J Virol 87:7837-7852. https://doi.org/10.1128/JVI.00481-13.
21. Ling S, Zhang C, Wang W, Cai X, Yu L, Wu F, Zhang L, Tian C. 2016. Combined approaches of EPR and NMR illustrate only one transmembrane helix in the human IFITM3. Sci Rep 6:24029. https://doi.org/10.1038/srep24029.
22. Weston S, Czieso S, White IJ, Smith SE, Kellam P, Marsh M. 2014. A membrane topology model for human interferon inducible transmembrane protein 1. PLoS One 9:e104341. https://doi.org/10.1371/journal.pone.0104341.
23. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N, Schwartz O. 2014. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 16:736-747. https://doi.org/10.1016/j.chom.2014.11.001.
24. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, Beaumont E, Roch E, Berger G, Mahieux R, Brand D, Roingeard P, Cimarelli A. 2014. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology 11:103. https://doi.org/10.1186/s12977-014-0103-y.
25. Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, Zheng YM, Freed EO, Liang C, Chen BK, Liu SL. 2015. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. Cell Rep 13:145-156. https://doi.org/10.1016/j.celrep.2015.08.055.
26. Qian J, Le Duff Y, Wang Y, Pan Q, Ding S, Zheng YM, Liu SL, Liang C. 2015. Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. Virology 474:10-18. https://doi.org/10.1016/j.virol.2014.10.015.
27. Wilkins J, Zheng YM, Yu J, Liang C, Liu SL. 2016. Nonhuman primate IFITM proteins are potent inhibitors of HIV and SIV. PLoS One 11: e0156739. https://doi.org/10.1371/journal.pone.0156739.
28. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, Martin MA. 1986. Production of acquired immunodeficiency syndromeassociated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59:284-291.
29. Collman R, Balliet J, Gregory S, Friedman H, Kolson D, Nathanson N, Srinivasan A. 1992. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 66:7517-7521.
30. Koup R, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68:4650-4655.
31. Li Y, Hui H, Burgess CJ, Price RW, Sharp PM, Hahn BH, Shaw GM. 1992. Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: evidence for limited defectiveness and complementation. J Virol 66:6587-6600.
32. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991. Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and-defective viral genomes. J Virol 65: 3973-3985.
33. Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, Kellam P, Finzi A, Borrow P, Hahn BH, Neil SJ. 2016. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. Cell Host Microbe 20:429-442. https://doi.org/10.1016/j.chom.2016.08.006.
34. Freed EO, Englund G, Martin MA. 1995. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J Virol 69:3949-3954.
35. Hamoudi M, Simon-Loriere E, Gasser R, Negroni M. 2013. Genetic diversity of the highly variable V1 region interferes with human immunodeficiency virus type 1 envelope functionality. Retrovirology 10:114. https://doi.org/10.1186/1742-4690-10-114.
36. Cordonnier A, Montagnier L, Emerman M. 1989. Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature 340:571-574. https://doi.org/10.1038/340571a0.
37. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR. 1991. Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253:71-74. https://doi.org/10.1126/science.1905842.
38. Fatkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11: 1170-1172. https://doi.org/10.1038/nm1319.
39. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. 2000. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44:1667-1673. https://doi.org/10.1128/AAC.44.6.1667-1673.2000.
40. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW. 1999. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 96:6359-6364. https://doi.org/10.1073/pnas.96.11.6359.
41. Thali M, Moore J, Furman C, Charles M, Ho D, Robinson J, Sodroski J. 1993. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67:3978-3988.
42. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, Longo NS, McKee K, O'Dell S, Louder MK, Wycuff DL, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong PD, Roederer M, Wyatt RT, Nabel GJ, Mascola JR. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861. https://doi.org/10.1126/science.1187659.
43. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. https://doi.org/10.1038/nature00939.
44. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. https://doi.org/10.1126/science. 1089591.
45. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853. https://doi.org/10.1038/nature02343.
46. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA, Smith JM, Packard BZ, Kuhn JH, Costantino J. 2013. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol 87:8451-8464. https://doi.org/10.1128/JVI.03382-12.
47. Warren CJ, Griffin LM, Little AS, Huang I-C, Farzan M, Pyeon D. 2014. The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus. PLoS One 9:e96579. https://doi.org/10.1371/journal.pone.0096579.
48. Ding S, Pan Q, Liu SL, Liang C. 2014. HIV-1 mutates to evade IFITM1 restriction. Virology 454-455:11-24. https://doi.org/10.1016/j.virol. 2014.01.020.
49. Jia R, Ding S, Pan Q, Liu SL, Qiao W, Liang C. 2015. The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PLoS One 10: e0118794. https://doi.org/10.1371/journal.pone.0118794.
50. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148. https://doi.org/10.1016/S0092-8674(00)81313-6.
51. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. 1996. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med 2:1244-1247. https://doi.org/10.1038/nm1196-1244.
52. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384:184-187. https://doi.org/10.1038/384184a0.
53. Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. 2014. Structure and immune recognition of trimeric prefusion HIV-1 Env. Nature 514:455-461. https://doi.org/10.1038/nature13808.
54. Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM. 2009. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387:414-426. https://doi.org/10.1016/j.virol.2009.02.022.
55. Letvin NL, Robinson S, Rohne D, Axthelm MK, Fanton JW, Bilska M, Palker TJ, Liao HX, Haynes BF, Montefiori DC. 2001. Vaccine-elicited V3 loopspecific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. J Virol 75:4165-4175. https://doi.org/10.1128/JVI.75.9.4165-4175.2001.
56. Zolla-Pazner S. 2005. Improving on nature: focusing the immune response on the V3 loop. Hum Antibodies 14:69-72.
57. Munro JB, Gorman J, Ma X, Zhou Z, Arthos J, Burton DR, Koff WC, Courter JR, Smith AB, III, Kwong PD, Blanchard SC, Mothes W. 2014. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 346:759-763. https://doi.org/10.1126/science.1254426.
58. Zhao X, Guo F, Liu F, Cuconati A, Chang J, Block TM, Guo J-T. 2014. Interferon induction of IFITM proteins promotes infection by human coronavirus OC43. Proc Natl Acad Sci U S A 111:6756-6761. https://doi.org/10.1073/pnas.1320856111.
59. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Sturzel CM, Mack K, Reith E, Engelhart S, Ciuffi A, Hornung V, Sauter D, Telenti A, Kirchhoff F. 2016. Guanylate binding protein (GBP) 5 is an interferoninducible inhibitor of HIV-1 infectivity. Cell Host Microbe 19:504-514. https://doi.org/10.1016/j.chom.2016.02.019.
60. Tada T, Zhang Y, Koyama T, Tobiume M, Tsunetsugu-Yokota Y, Yamaoka S, Fujita H, Tokunaga K. 2015. MARCH8 inhibits HIV-1 infection by reducing virion incorporation of envelope glycoproteins. Nat Med 21: 1502-1507. https://doi.org/10.1038/nm.3956.
61. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J. 2015. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526: 212-217. https://doi.org/10.1038/nature15399.
62. Usami Y, Wu Y, Gottlinger HG. 2015. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526:218-223. https://doi.org/10.1038/nature15400.
63. Krowicka H, Robinson JE, Clark R, Hager S, Broyles S, Pincus SH. 2008. Use of tissue culture cell lines to evaluate HIV antiviral resistance. AIDS Res Hum Retroviruses 24:957-967. https://doi.org/10.1089/aid.2007.0242.
64. Harada S, Koyanagi Y, Yamamoto N. 1985. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229:563-566. https://doi.org/10.1126/science.2992081.
65. Cavrois M, de Noronha C, Greene WC. 2002. A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. Nat Biotechnol 20:1151-1154. https://doi.org/10.1038/nbt745.
66. Cavrois M, Neidleman J, Bigos M, Greene WC. 2004. Fluorescence resonance energy transfer-based HIV-1 virion fusion assay. Methods Mol Biol 263:333-343.
67. Ding S, Medjahed H, Prévost J, Coutu M, Xiang SH, Finzi A. 2016. Lineage-specific differences between the gp120 inner domain layer 3 of human immunodeficiency virus and that of simian immunodeficiency virus. J Virol 90:10065-10073. https://doi.org/10.1128/JVI.01215-16.
68. Desormeaux A, Coutu M, Medjahed H, Pacheco B, Herschhorn A, Gu C, Xiang SH, Mao Y, Sodroski J, Finzi A. 2013. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol 87:2549-2562. https://doi.org/10.1128/JVI.03104-12.
69. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, Kassa A, Danek B, Pancera M, Kwong PD, Sodroski J. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37:656-667. https://doi.org/10.1016/j.molcel.2010.02.012.